Adagio Elevates Interim Chief Executive David Hering To Permanent CEO

Adagio Therapeutics, Inc. (ADGI), a company focused on the antibody-based solutions for infectious diseases, said on Tuesday that its interim Chief Executive and Chief Operating Officer David Hering has now been appointed as permanent CEO.

Marc Elia, Chair of Adagio's Board, said: "A thorough process underlined Dave's core skills and deep expertise. He is the ideal person to lead Adagio through its next phase of growth…Dave has a unique track record leading organizations focused on infectious disease medicines, including the launch of the first and market leading Covid-19 vaccine during his time at Pfizer…"

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sysco Corp. (SYY) Tuesday reported a more than a three-times surge in fourth-quarter earnings, supported by 17.5 percent growth in sales. The company projects fiscal 2023 adjusted earnings to grow. Earnings for the quarter spiked to $509.99 million from $151.09 million last year. On a per share basis,... Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly...
Follow RTT